217 related articles for article (PubMed ID: 34648658)
21.
Cao CH; Liu R; Lin XR; Luo JQ; Cao LJ; Zhang QJ; Lin SR; Geng L; Sun ZY; Ye SK; Yu ZY; Shi Y; Xia X
Int J Biol Sci; 2021; 17(7):1744-1756. PubMed ID: 33994859
[TBL] [Abstract][Full Text] [Related]
22. Type I conventional dendritic cells and CD8
Kirchner J; Plesca I; Rothe R; Resag A; Löck S; Benešová I; Rupp L; Linge A; Wehner R; Krause M; Schmitz M
Front Immunol; 2024; 15():1414298. PubMed ID: 38938577
[TBL] [Abstract][Full Text] [Related]
23. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
25. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
26. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
[TBL] [Abstract][Full Text] [Related]
27. The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenografts.
Linge A; Patil S; Grosser M; Lohaus F; Gurtner K; Kemper M; Gudziol V; Haim D; Nowak A; Tinhofer I; Zips D; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Gani C; Jöhrens K; Baretton GB; Löck S; Baumann M; Krause M;
Radiother Oncol; 2024 Feb; 191():110055. PubMed ID: 38109944
[TBL] [Abstract][Full Text] [Related]
28. Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG.
Linge A; Löck S; Gudziol V; Nowak A; Lohaus F; von Neubeck C; Jütz M; Abdollahi A; Debus J; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Bayer C; Belka C; Pigorsch S; Combs SE; Welz S; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Baumann M; Krause M;
Clin Cancer Res; 2016 Jun; 22(11):2639-49. PubMed ID: 26755529
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the cancer stem cell marker DCLK1 in patients with lymph node metastases of head and neck cancer.
Kadletz L; Kenner L; Wiebringhaus R; Jank B; Mayer C; Gurnhofer E; Konrad S; Heiduschka G
Pathol Res Pract; 2019 Dec; 215(12):152698. PubMed ID: 31706685
[TBL] [Abstract][Full Text] [Related]
30. Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.
Descamps G; Karaca Y; Lechien JR; Kindt N; Decaestecker C; Remmelink M; Larsimont D; Andry G; Hassid S; Rodriguez A; Khalife M; Journe F; Saussez S
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2185-96. PubMed ID: 27370781
[TBL] [Abstract][Full Text] [Related]
31. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
32. Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas.
Dok R; Bamps M; Glorieux M; Zhao P; Sablina A; Nuyts S
Int J Cancer; 2020 Feb; 146(4):1075-1085. PubMed ID: 31283004
[TBL] [Abstract][Full Text] [Related]
33. Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients.
Li J; Tang LL; Ma J
BMC Cancer; 2022 Jun; 22(1):714. PubMed ID: 35768785
[TBL] [Abstract][Full Text] [Related]
34. Preferential activation of the hedgehog pathway by epigenetic modulations in HPV negative HNSCC identified with meta-pathway analysis.
Fertig EJ; Markovic A; Danilova LV; Gaykalova DA; Cope L; Chung CH; Ochs MF; Califano JA
PLoS One; 2013; 8(11):e78127. PubMed ID: 24223768
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation regulated microRNAs in HPV-16-induced head and neck squamous cell carcinoma (HNSCC).
Sannigrahi MK; Sharma R; Singh V; Panda NK; Rattan V; Khullar M
Mol Cell Biochem; 2018 Nov; 448(1-2):321-333. PubMed ID: 29455435
[TBL] [Abstract][Full Text] [Related]
36. Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
Maihoefer C; Schüttrumpf L; Macht C; Pflugradt U; Hess J; Schneider L; Woischke C; Walch A; Baumeister P; Kirchner T; Zitzelsberger H; Belka C; Ganswindt U
Radiat Oncol; 2018 Jul; 13(1):123. PubMed ID: 29970111
[TBL] [Abstract][Full Text] [Related]
37. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.
Virani S; Bellile E; Bradford CR; Carey TE; Chepeha DB; Colacino JA; Helman JI; McHugh JB; Peterson LA; Sartor MA; Taylor JM; Walline HM; Wolf GT; Rozek LS
BMC Cancer; 2015 Oct; 15():825. PubMed ID: 26518708
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
39. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
40. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.
Foy JP; Bazire L; Ortiz-Cuaran S; Deneuve S; Kielbassa J; Thomas E; Viari A; Puisieux A; Goudot P; Bertolus C; Foray N; Kirova Y; Verrelle P; Saintigny P
BMC Med; 2017 Sep; 15(1):165. PubMed ID: 28859688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
